Dihexa.

Quick Overview.

Dihexa (also known as PNB-0408) is a synthetic oligopeptide derived from Angiotensin IV. It was developed by researchers at Washington State University with the specific goal of treating Alzheimer's disease and other neurodegenerative disorders. Unlike many older nootropics that simply increase blood flow or neurotransmitter levels, Dihexa is designed to physically rebuild the brain by stimulating the formation of new synapses (synaptogenesis).[1]

In the biohacking community, Dihexa is often referred to as the "God Peptide" for cognitive enhancement. It is claimed to be millions of times more potent than Brain-Derived Neurotrophic Factor (BDNF) at building new neural connections. While the preclinical data in animal models is astonishing, it is important to note that Dihexa has not yet completed human clinical trials, making it a highly experimental compound.[2]

• Primary Use Case: Extreme cognitive enhancement, memory recovery, and potential treatment for traumatic brain injury (TBI) or Alzheimer's.
• Mechanism: High-affinity binding to Hepatocyte Growth Factor (HGF) and its receptor, c-Met, which drives profound synaptogenesis and neuroplasticity.[3]
• Who it is for: Advanced biohackers looking for long-term structural improvements to memory and learning capacity.
• Who it is NOT for: Beginners, or anyone with an active cancer diagnosis (due to its mechanism of action).

The Protocol & Usage Guide.

confidence_tier: experimental

Dihexa is unique among peptides because it is orally bioavailable and can cross the blood-brain barrier effectively. However, because of its poor solubility in water, it is often dissolved in DMSO (Dimethyl sulfoxide) for transdermal (topical) application, or taken orally in lipid-bound capsules.[4]

Standard Dosing Schedule

Cycle Length & Discontinuation Protocol

• Cycle Length: Because Dihexa causes structural changes to the brain (building new synapses), it does not need to be taken indefinitely. A standard cycle is 4 to 8 weeks, followed by an extended break.
• The "Integration" Phase: The new synapses built by Dihexa must be utilized to become permanent. Users are highly encouraged to learn a new skill (e.g., a language, an instrument, or complex mathematics) while on cycle to "wire in" the new neural pathways.
• Discontinuation: No tapering is required. The cognitive benefits are often reported to persist long after the drug is stopped.

Nutritional Support & Recommended Supplements.

confidence_tier: community

Safety, Interactions & Side Effect Management.

confidence_tier: experimental

Side Effect Profile

Contraindications

• Absolute: Individuals with an active cancer diagnosis or a strong family history of cancer. The HGF/c-Met pathway that Dihexa activates is also heavily involved in tumor metastasis and angiogenesis (blood vessel growth for tumors).
• Relative: Pregnant or nursing women, due to a complete lack of human safety data.

Common Stacks & Combinations.

confidence_tier: community

Body Composition & Training Guide.

confidence_tier: well-established

• Not a Muscle Builder: Dihexa has no direct effect on muscle hypertrophy or fat loss.
• Motor Skill Acquisition: Because Dihexa drastically accelerates the brain's ability to form new connections, it is highly theoretical but plausible that it could accelerate the acquisition of complex physical motor skills (e.g., gymnastics, martial arts, or golf swings) if the user practices those skills intensely while on cycle.

Storage, Handling & Accessibility.

confidence_tier: well-established

• Storage: Raw Dihexa powder should be stored in a cool, dry place away from light. If dissolved in DMSO for transdermal use, it should be kept at room temperature (DMSO freezes in the refrigerator).
• WADA Status: Not explicitly listed, but falls under the blanket ban of unapproved experimental peptides.
• Cost & Accessibility: Available through "research chemical" and peptide vendors online. It is relatively expensive compared to older nootropics like racetams.

Bloodwork Monitoring Guide.

confidence_tier: experimental

Because Dihexa is highly experimental and lacks long-term human safety data, standard bloodwork cannot accurately monitor its specific effects.

• Precautionary: Users should ensure they have standard comprehensive metabolic panels (CMP) and complete blood counts (CBC) to ensure baseline health before experimenting with unapproved compounds.

Comparison to Similar Compounds.

confidence_tier: well-established

Deep Dive (For Advanced Researchers).

confidence_tier: well-established

The HGF / c-Met Pathway

Unlike most nootropics that target neurotransmitter systems (like acetylcholine or dopamine) or standard neurotrophins (like BDNF), Dihexa targets the Hepatocyte Growth Factor (HGF) and its receptor, c-Met.

• Mechanism: Dihexa binds to HGF with high affinity, causing it to dimerize and activate the c-Met receptor. In the brain, the HGF/c-Met system is a profound driver of dendritic spine formation and synaptogenesis.
• Potency: In preclinical assays measuring the formation of new dendritic spines in hippocampal neurons, Dihexa was found to be seven orders of magnitude (10,000,000 times) more potent than BDNF.[5][6]

Reversing Alzheimer's in Animal Models

The most compelling data for Dihexa comes from its effects on animal models of Alzheimer's disease (specifically the APP/PS1 mouse model).

• In these studies, mice with severe, chemically induced or genetically engineered cognitive deficits were given Dihexa. The compound not only halted the cognitive decline but actively reversed it, restoring the animals' performance in spatial memory tasks (like the Morris water maze) to the level of healthy, normal mice.
• Histological examination of the brains of these mice showed a massive restoration of synaptic connectivity that had been destroyed by amyloid-beta plaques.[7][8]

The Cancer Caveat

The primary hurdle preventing Dihexa from becoming a mainstream pharmaceutical is its mechanism of action. The HGF/c-Met pathway is a known oncogenic driver. Many aggressive cancers hijack this exact pathway to promote metastasis and angiogenesis. While Dihexa does not cause cancer (it is not a mutagen), if a user has an existing, undiagnosed micro-tumor, activating the c-Met pathway could theoretically act as "rocket fuel" for that tumor, accelerating its growth and spread. This is the primary reason human clinical trials have been delayed.[9]

Frequently Asked Questions (FAQ).

confidence_tier: community

Q: Do I have to inject Dihexa? A: No. Dihexa was specifically engineered to be orally bioavailable and to cross the blood-brain barrier. It can be taken in capsules or applied transdermally using a DMSO carrier.

Q: Will the cognitive benefits disappear when I stop taking it? A: Theoretically, no. Because Dihexa physically builds new synapses, those connections remain after the drug is cleared from your system—provided you actively use those neural pathways. "Use it or lose it" applies heavily here.

Q: Is it safe? A: It is highly experimental. While no acute toxicity has been reported in animal models, the lack of human clinical trials and the theoretical risk of accelerating existing cancers make it a "use at your own risk" compound.

International Regulatory Status.

confidence_tier: well-established

Decision Tree.

confidence_tier: community

[Goal: Extreme Cognitive Enhancement or TBI Recovery?]
  |
  +-- Do you have an active cancer diagnosis or high genetic risk?
        |
        +-- (Yes) -> DO NOT USE DIHEXA. The c-Met pathway can accelerate tumor growth.
        |
        +-- (No) -> Are you willing to accept the risks of an experimental compound?
              |
              +-- (No) -> Use Semax or Cerebrolysin instead.
              |
              +-- (Yes) -> Take 10-20mg orally or 5-10mg transdermally daily.
                           Actively study or learn new skills while on cycle.
                           Limit cycle to 4-8 weeks.

Schema.org Data.

{
  "@context": "https://schema.org",
  "@type": "MedicalEntity",
  "name": "Dihexa",
  "alternateName": ["PNB-0408", "N-hexanoic-Tyr-Ile-(6) aminohexanoic amide"],
  "description": "An experimental, orally active oligopeptide derived from Angiotensin IV. Designed to treat Alzheimer's disease by profoundly stimulating synaptogenesis via the HGF/c-Met pathway. Highly potent but lacks human clinical trials.",
  "legalStatus": {
    "@type": "DrugLegalStatus",
    "description": "Unapproved experimental compound. Sold as a research chemical."
  }
}

What we cited.